Synthesis and characterization of celecoxib derivatives as possible anti-inflammatory, analgesic, antioxidant, anticancer and anti-HCV agents

Molecules

Volumn 18, Issue 3, 2013, Pages 3595-3614

  Küçükgüzel, Ş Güniz ^a   Coşkun, Inci ^a   Aydin, Sevil ^a   Aktay, Göknur ^b   Gürsoy, Şule ^b   Çevik, Özge ^a,c   Özakpinar, Özlem Bingöl ^a   Özsavci, Derya ^a   Şener, Azize ^a   Kaushik Basu, Neerja ^d   Basu, Amartya ^d   Talele, Tanaji T ^e  

^a MARMARA UNIVERSITY   (Turkey)

^b INONU UNIVERSITY   (Turkey)

^c CUMHURIYET UNIVERSITY   (Turkey)

^d RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^e ST JOHN'S UNIVERSITY   (United States)

Author keywords

Anti inflammatory; Anticancer; Celecoxib; Hepatitis C NS5B; Sulfonylthiourea

Indexed keywords

ANTINEOPLASTIC AGENT; ANTIOXIDANT; ANTIVIRUS AGENT; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; ISOTHIOCYANIC ACID DERIVATIVE; NS 5 PROTEIN, HEPATITIS C VIRUS; NS-5 PROTEIN, HEPATITIS C VIRUS; PYRAZOLE DERIVATIVE; SULFONAMIDE; SULFONYLUREA DERIVATIVE; THIAZOLIDINE DERIVATIVE; VIRUS PROTEIN; PROTEIN BINDING;

ANIMAL; ARTICLE; BAGG ALBINO MOUSE; CHEMICALLY INDUCED DISORDER; CHEMISTRY; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; DRUG SCREENING; EDEMA; ENZYME ACTIVE SITE; ENZYMOLOGY; FEMALE; HEPATITIS C VIRUS; HINDLIMB; HUMAN; LIPID PEROXIDATION; MALE; MOUSE; OXIDATIVE STRESS; PATHOLOGY; PROTEIN BINDING; STOMACH ULCER; SYNTHESIS; TUMOR CELL LINE; ANTAGONISTS AND INHIBITORS; CHEMICALLY INDUCED; DRUG EFFECTS; HEPACIVIRUS; TOXICITY;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTIOXIDANTS; ANTIVIRAL AGENTS; CATALYTIC DOMAIN; CELL LINE, TUMOR; CYCLOOXYGENASE 2 INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; EDEMA; FEMALE; HEPACIVIRUS; HINDLIMB; HUMANS; ISOTHIOCYANATES; LIPID PEROXIDATION; MALE; MICE; MICE, INBRED BALB C; OXIDATIVE STRESS; PROTEIN BINDING; PYRAZOLES; STOMACH ULCER; SULFONAMIDES; SULFONYLUREA COMPOUNDS; THIAZOLIDINES; VIRAL NONSTRUCTURAL PROTEINS;

EID: 84875601300     PISSN: None     EISSN: 14203049     Source Type: Journal    
DOI: 10.3390/molecules18033595     Document Type: Article

References (42)

1. Vane, J.R. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat. New Biol. 1971, 231, 232-235.
2. Wu, T. Cyclooxygenase-2 in hepatocellular carcinoma. Cancer Treat. Rev. 2006, 32, 28-44.
3. Koga, H.; Sakisaka, S.; Ohishi, M.; Kawaguchi, T.; Taniguchi, E.; Sasatomi, K.; Harada, M.; Kusaba, T.; Tanaka, M.; Kimura, R.; et al. Expression of cyclooxygenase-2 in human hepatocellular carcinoma: Relevance to tumor dedifferentiation. Hepatology 1999, 29, 688-696.
4. Cervello, M.; Montalco, G. Cyclooxygenases in hepatocellular carcinoma. World J. Gastroenterol. 2006, 12, 5113-5121.
5. Pozzi, A.; Yan, X.; Macias-Perez, I.; Wei, S.; Hata, A.N.; Breyer, R.M.; Morrow, J.D.; Capdevila, J.H. Colon carcinoma cell growth is associated with prostaglandin E2/EP4 receptor-evoked ERK activation. J. Biol. Chem. 2004, 279, 29797-29804.
6. Dermond, O.; Rüegg, C. Inhibition of tumor angiogenesis by non-steroidal anti-inflammatory drugs: Emerging mechanisms and therapeutic perspectives. Drug Resist. Updat. 2001, 4, 314-321.
7. Thun, M.J.; Henley, S.J.; Patrono, C. Nonsteroidal anti-inflammatory drugs as anticancer agents: Mechanistic, pharmacologic, and clinical issues. J. Natl. Cancer Inst. 2002, 94, 252-266.
8. Halliwell, B. Drug antioxidant effects. A basis for drug selection? Drugs 1991, 42, 569-605.
9. Djordjevic, V.B. Free radicals in cell biology. Int. Rev. Cytol. 2004, 237, 57-89.
10. Goldenthal, M.J.; Marin-Garcia, J. Mitochondrial signaling pathways: A receiver/integrator organelle. Mol. Cell. Biochem. 2004, 262, 1-16.
11. Pereira, C.V.; Moreira, A.C.; Pereira, S.P.; Machado, N.G.; Carvalho, F.S.; Sardão, V.A.; Oliveira, P.J. Investigating Drug-induced Mitochondrial Toxicity: A Biosensor to Increase Drug Safety? Curr. Drug Saf. 2009, 4, 34-54.
12. Rostom, S.A.; Shalaby, M.A.; El-Demellawy, M.A. Polysubstituted pyrazoles, part 5. Synthesis of new 1-(4-chlorophenyl)-4-hydroxy-1H-pyrazole-3- carboxylic acid hydrazide analogs and some derived ring systems. A novel class of potential antitumor and anti-HCV agents. Eur. J. Med. Chem. 2003, 38, 959-974.
13. Riyadh, S.M.; Farghaly, T.A.; Abdallah, M.A.; Abdalla, M.M.; Abd El-Aziz, M.R. New pyrazoles incorporating pyrazolylpyrazole moiety: Synthesis, anti-HCV and antitumor activity. Eur. J. Med. Chem. 2010, 45, 1042-1050.
14. Popovici-Muller, J.; Shipps, G.W., Jr.; Rosner, K.E.; Deng, Y.; Wang, T.; Curran, P.J.; Brown, M.A.; Siddiqui, M.A.; Cooper, A.B.; Duca, J.; et al. Pyrazolo[1,5-a]pyrimidine-based inhibitors of HCV polymerase. Bioorg. Med. Chem. 2009, 19, 6331-6336.
15. Farghaly, T.A.; Abass, I.M.; Abdalla, M.M.; Mahgoub, R.O.A. Synthesis and pharmacological activities of fused pyrimidinones. World J. Chem. 2011, 6, 8-18.
16. Okamoto, M.; Sakai, M.; Goto, Y.; Salim, M.T.; Baba, C.; Goto, K.; Watashi, K.; Shimotohno, K.; Baba, M. Anti-bovine viral diarrhoea virus and hepatitis C virus activity of the cyclooxygenase inhibitor SC-560. Antivir. Chem. Chemother. 2009, 20, 47-54.
17. Bock, J.M.; Menon, S.G.; Sinclair, L.L.; Bedford, N.S.; Goswami, P.C.; Domann F.E.; Trask, D.K. Celecoxib toxicity is cell cycle phase specific. Cancer Res. 2007, 67, 3801-3808.
18. Kern, M.A.; Schubert, D.S.; Sahi, D.; Schöneweiss, M.M.; Moll, I.; Haugg, A.M.; Dienes, H.P.; Breuhahn, K.; Schirmacher, P. Proapoptotic and antiproliferative potential of selective cyclooxygenase-2 inhibitors in human liver tumor cells. Hepatology 2002, 36, 885-894.
19. Rostom, S.A.F. Synthesis and in vitro antitumor evaluation of some indeno[1,2-c]pyrazol(in)es substituted with sulfonamide, sulfonylurea(-thiourea) pharmacophores, and some derived thiazole ring systems. Bioorg. Med. Chem. 2006, 14, 6475-6485.
20. Bekhit, A.A.; Ashour, H.M.; Abdel Ghany, Y.S.; Bekhit, Ael-D.; Baraka, A. Synthesis and biological evaluation of some thiazolyl and thiadiazolyl derivatives of 1H-pyrazole as anti-inflammatory antimicrobial agents. Eur. J. Med. Chem. 2008, 43, 456-463.
21. Tsurumi, K.; Kyuki, K.; Niwa, M.; Kokuba, S.; Fujimura, H. Pharmacological investigations of the new antiinflammatory agent 2-(10,11-dihydro-10-oxodibenzo[b,f]thiepin-2-yl)propionic acid. 1st Communication: Inhibitory effects on rat paw edema. Arzneim. Forsch. 1986, 36, 1796-1800.
22. Gavalas, A.; Kourounakis, L.; Litina, D.; Kourounakis, P. Anti-inflammatory and immuno-modulating effects of the novel agent γ-(2-aminoethylamino)-2-butyrothienone. Inhibitory effects on mouse paw oedema. Arzneim. Forsch/Drug Res. 1991, 41, 423-426.
23. Nantel, F.; Denis, D.; Gordon, R.; Northey, A.; Cirino, M.; Metters, K.M.; Chan, C.C. Distribution and regulation of cyclooxygenase-2 in carrageenan-induced inflammation. Br. J. Pharmacol. 1999, 128, 853-859.
24. Meller, S.T.; Cummings, C.P.; Traub, R.J.; Gebhart, G.F. The role of nitric oxide in the development and maintenance of hyperalgesia produced by intraplantar injection of carrageenan in the rat. Neuroscience 1994, 60, 367-374.
25. Bragt, P.C.; Bansberg, J.I.; Bonta, I.L. Antiinflammatory effects of free radical scavengers and antioxidants: Further support for proinflammatory roles of endogenous hydrogen peroxide and lipid peroxides. Inflammation 1980, 4, 289-299.
26. Hillegas, L.M.; Griswold, D.E.; Brickson, B.; Albrightson-Winslow C. Assessment of myeloperoxidase activity in whole rat kidney. J. Pharmacol. Methods 1990, 24, 285-295.
27. Mylorie, A.A.; Collins, H.; Umbles, C.; Kyle, J. Erythrocyte superoxide dismutase activity and other parameters of copper status in rats ingesting lead acetate. Toxicol. Appl. Pharmacol. 1986, 82, 512-520.
28. Beutler, E. Glutathione in Red Blood Cell Metabolism. In A Manual of Biochemical Methods; Grune & Stratton: New York, NY, USA, 1975; pp. 112-114.
29. National Cancer Institute. Developmental Therapeutics Program: Screening Services. Selection Guidelines for Small Molecule Structures for Screening. Available from http://dtp.nci.nih.gov/branches/btb/ivclsp.html. (accessed on 25 September 2012).
30. Chen, Y.; Bopda-Waffo, A.; Basu, A.; Krishnan, R.; Silberstein, E.; Taylor, D.R.; Talele, T.T.; Arora, P.; Kaushik-Basu, N. Characterization of aurintricarboxylic acid as a potent hepatitis C virus replicase inhibitor. Antivir. Chem. Chemother. 2009, 20, 19-36.
31. Kaushik-Basu, N.; Bopda-Waffo, A.; Talele, T.T.; Basu, A.; Chen, Y.; Kucukguzel, S.G. 4-Thiazolidinones: A novel class of hepatitis C virus NS5B polymerase inhibitors. Front. Biosci. 2008, 13, 3857-3868.
32. Kaushik-Basu, N.; Bopda-Waffo, A.; Talele, T.T.; Basu, A.; Costa, P.R.; da Silva, A.J.; Sarafianos, S.G.; Noël, F. Identification and characterization of coumestans as novel HCV NS5B polymerase inhibitors. Nucleic Acids Res. 2008, 36, 1482-1496.
33. Narjes, F.; Crescenzi, B.; Ferrara, M.; Habermann, J.; Colarusso, S.; Ferreira Mdel, R.; Stansfield, I.; Mackay, A.C.; Conte, I.; Ercolani, C; et al. Discovery of (7R)-14-cyclohexyl-7-{[2- (dimethylamino)ethyl](methyl)amino}-7,8- dihydro-6H-indolo[1,2-e][1,5]benzoxazocine-11-carboxylic acid (MK-3281), a potent and orally bioavailable finger-loop inhibitor of the hepatitis C virus NS5B polymerase. J. Med. Chem. 2011, 54, 289-301.
34. Li, H.; Tatlock, J.; Linton, A.; Gonzalez, J.; Jewell, T.; Patel, L.; Ludlum, S.; Drowns, M.; Rahavendran, S.V.; Skor, H.; et al. Discovery of (R)-6-cyclopentyl-6-(2-(2,6-diethylpyridin-4- yl)ethyl)-3-((5,7-dimethyl-[1,2,4] triazolo[1,5-a]pyrimidin-2-yl)methyl)-4-hydroxy-5,6-dihydropyran- 2-one (PF-00868554) as a potent and orally available hepatitis C virus polymerase inhibitor. J. Med. Chem. 2009, 52, 1255-1258.
35. Chen, K.X.; Vibulbhan, B.; Yang, W.; Sannigrahi, M.; Velazquez, F.; Chan, T.Y.; Venkatraman, S.; Anilkumar, G.N.; Zeng, Q.; Bennet, F.; et al. Structure-activity relationship (SAR) development and discovery of potent indole-based inhibitors of the hepatitis C virus (HCV) NS5B polymerase. J. Med. Chem. 2012, 55, 754-765.
36. Hang, J.Q.; Yang, Y.; Harris, S.F.; Leveque, V.; Whittington, H.J.; Rajyaguru, S.; Ao-Ieong, G.; McCown, M.F.; Wong, A.; Giannetti, A.M.; et al. Slow binding inhibition and mechanism of resistance of non-nucleoside polymerase inhibitors of hepatitis C virus. J. Biol. Chem. 2009, 284, 15517-15529.
37. Kasahara, Y.; Hikino, H.; Tsurufuji, S.; Watanabe, M.; Ohuchi, K. Antiinflammation actions of ephedrines in acute inflammations. Planta Med. 1985, 51, 325-331.
38. Koster, R.; Anderson, M.; De Beer, E.J. Acetic acid for analgesic screening. Fed. Proc. 1959, 18, 412-416.
39. Ohkawa, H.; Ohishi, N.; Yagi, K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal. Biochem. 1979, 95, 351-358.
40. Jammal, S.; Smith, J.C. Effects of cadmium on glutathione peroxidase, superoxide dismutase and lipid peroxidation in the rat heart: A possible mechanism of cadmium cardiotoxicity. Toxicol. Appl. Pharmacol. 1985, 80, 33-42.
41. Willoughby, D.A.; Moore, A.R.; Colville-Nash, P.R.; COX-1, COX-2, and COX-3 and the future treatment of chronic inflammatory disease. Lancet 2000, 355, 646-648.
42. Holsapple, M.P.; Schnur, M.; Yim, G.K. Pharmacological modulation of edema mediated by prostaglandin, serotonin and histamine. Agents Actions 1980, 10, 368-373.